470.52 USD
+4.91 (+1.05%)
At close: Feb 4, 2026
470.52 USD
0 (0%)
After Hours: 2/4/2026, 6:56:58 PM
Taking everything into account, VRTX scores 6 out of 10 in our fundamental rating. VRTX was compared to 524 industry peers in the Biotechnology industry. While VRTX has a great profitability rating, there are some minor concerns on its financial health. VRTX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make VRTX suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
- VRTX had positive earnings in the past year.
- In the past year VRTX had a positive cash flow from operations.
- VRTX had positive earnings in 4 of the past 5 years.
- VRTX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- VRTX has a Return On Assets of 14.78%. This is amongst the best in the industry. VRTX outperforms 95.61% of its industry peers.
- Looking at the Return On Equity, with a value of 21.22%, VRTX belongs to the top of the industry, outperforming 96.37% of the companies in the same industry.
- VRTX has a Return On Invested Capital of 17.58%. This is amongst the best in the industry. VRTX outperforms 97.14% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for VRTX is in line with the industry average of 18.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 17.58% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)19.67%
ROIC(5y)20.26%
1.3 Margins
- The Profit Margin of VRTX (31.35%) is better than 96.18% of its industry peers.
- With an excellent Operating Margin value of 38.70%, VRTX belongs to the best of the industry, outperforming 98.09% of the companies in the same industry.
- VRTX's Operating Margin has improved in the last couple of years.
- VRTX's Gross Margin of 86.28% is amongst the best of the industry. VRTX outperforms 89.12% of its industry peers.
- In the last couple of years the Gross Margin of VRTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VRTX is creating value.
- VRTX has less shares outstanding than it did 1 year ago.
- VRTX has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, VRTX has an improved debt to assets ratio.
2.2 Solvency
- There is no outstanding debt for VRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.97
WACC8.92%
2.3 Liquidity
- VRTX has a Current Ratio of 2.36. This indicates that VRTX is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.36, VRTX is not doing good in the industry: 71.56% of the companies in the same industry are doing better.
- A Quick Ratio of 2.00 indicates that VRTX should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.00, VRTX is doing worse than 73.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
- VRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3303.92%, which is quite impressive.
- VRTX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
- Looking at the last year, VRTX shows a quite strong growth in Revenue. The Revenue has grown by 10.33% in the last year.
- Measured over the past years, VRTX shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
- Based on estimates for the next years, VRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 150.51% on average per year.
- The Revenue is expected to grow by 9.75% on average over the next years. This is quite good.
EPS Next Y6337.86%
EPS Next 2Y737.83%
EPS Next 3Y328.22%
EPS Next 5Y150.51%
Revenue Next Year10.06%
Revenue Next 2Y9.3%
Revenue Next 3Y9.36%
Revenue Next 5Y9.75%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 27.10, the valuation of VRTX can be described as expensive.
- Based on the Price/Earnings ratio, VRTX is valued cheaper than 93.70% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.25. VRTX is around the same levels.
- With a Price/Forward Earnings ratio of 23.11, VRTX is valued on the expensive side.
- Based on the Price/Forward Earnings ratio, VRTX is valued cheaper than 92.94% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of VRTX to the average of the S&P500 Index (27.50), we can say VRTX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.1 | ||
| Fwd PE | 23.11 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VRTX indicates a rather cheap valuation: VRTX is cheaper than 93.70% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of VRTX indicates a rather cheap valuation: VRTX is cheaper than 93.70% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.77 | ||
| EV/EBITDA | 23.61 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of VRTX may justify a higher PE ratio.
- A more expensive valuation may be justified as VRTX's earnings are expected to grow with 328.21% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y737.83%
EPS Next 3Y328.22%
5. Dividend
5.1 Amount
- No dividends for VRTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
470.52
+4.91 (+1.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-12 2026-02-12/amc
Inst Owners97.56%
Inst Owner Change-1.96%
Ins Owners0.13%
Ins Owner Change8.21%
Market Cap119.38B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.92
Price Target507.58 (7.88%)
Short Float %1.75%
Short Ratio3.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)1.31%
PT rev (3m)3.2%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)4.06%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)-0.82%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.1 | ||
| Fwd PE | 23.11 | ||
| P/S | 10.18 | ||
| P/FCF | 35.77 | ||
| P/OCF | 32.11 | ||
| P/B | 6.89 | ||
| P/tB | 7.56 | ||
| EV/EBITDA | 23.61 |
EPS(TTM)17.36
EY3.69%
EPS(NY)20.36
Fwd EY4.33%
FCF(TTM)13.15
FCFY2.8%
OCF(TTM)14.65
OCFY3.11%
SpS46.21
BVpS68.26
TBVpS62.28
PEG (NY)0
PEG (5Y)N/A
Graham Number163.29
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 17.58% | ||
| ROICexc | 25.42% | ||
| ROICexgc | 28.48% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)19.67%
ROIC(5y)20.26%
ROICexc(3y)48.65%
ROICexc(5y)54.9%
ROICexgc(3y)69.59%
ROICexgc(5y)85.25%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.92%
ROIC/WACC1.97
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6337.86%
EPS Next 2Y737.83%
EPS Next 3Y328.22%
EPS Next 5Y150.51%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.06%
Revenue Next 2Y9.3%
Revenue Next 3Y9.36%
Revenue Next 5Y9.75%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year824.9%
EBIT Next 3Y127.59%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VRTX FAQ
Can you provide the ChartMill fundamental rating for VERTEX PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to VRTX.
What is the valuation status for VRTX stock?
ChartMill assigns a valuation rating of 7 / 10 to VERTEX PHARMACEUTICALS INC (VRTX). This can be considered as Undervalued.
Can you provide the profitability details for VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC (VRTX) has a profitability rating of 7 / 10.
What is the valuation of VERTEX PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VRTX) is 27.1 and the Price/Book (PB) ratio is 6.89.
How financially healthy is VERTEX PHARMACEUTICALS INC?
The financial health rating of VERTEX PHARMACEUTICALS INC (VRTX) is 6 / 10.